Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Drug Level and Investigation of Novel Substances Indicated Downstream Effect in Glioblastoma

NCT03151772 is registered in ClinicalTrials.gov with Sahlgrenska University Hospital as lead sponsor.

NCT NCT03151772
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03151772 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Drug Level and Investigation of Novel Substances Indicated Downstream Effect in Glioblastoma
Lead sponsor
Sahlgrenska University Hospital
Phase
Phase 1
Overall status
Terminated
Start date
January 29, 2018
Completion date
September 24, 2020
Enrollment
3 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma